Results 21 to 30 of about 530,731 (290)

Overcoming challenges for CD3-bispecific antibody therapy in solid tumors [PDF]

, 2021
Simple SummaryCD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is currently successfully used in the clinic to treat tumors in the blood and
Thorbald van Hall, Kemper, K., Engelberts, P., Janine Schuurman, Jim Middelburg, Kristel Kemper, Middelburg, J., Labrijn, A.F., Hall, T. van, Aran F. Labrijn, Patrick Engelberts, Schuurman, J.   +11 more
core   +1 more source

Bispecific antibodies and their applications [PDF]

Journal of Hematology & Oncology, 2015
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Fan, Gaowei, Wang, Zujian, Hao, Mingju, Li, Jinming   +3 more
openaire   +2 more sources

Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Scientific Reports, 2023
Complement-dependent cytotoxicity (CDC), which eliminates aberrant target cells through the assembly and complex formation of serum complement molecules, is one of the major effector functions of anticancer therapeutic antibodies.
Sang Min Lee, Sung-Won Min, Hyeong Sun Kwon, Gong-Deuk Bae, Ji Hae Jung, Hye In Park, Seung Hyeon Lee, Chung Su Lim, Byoung Joon Ko, Ji Chul Lee, Sang Taek Jung   +10 more
doaj   +1 more source

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics

mAbs, 2021
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with two different heavy chains is greatly simplified if the light chains can be the ...
Kathryn H. Ching, Kimberley Berg, Kevin Reynolds, Darlene Pedersen, Alba Macias, Yasmina N. Abdiche, William D. Harriman, Philip A. Leighton   +7 more
doaj   +1 more source

Targeting hepatocytes via the asialoglycoprotein-receptor [PDF]

, 2010
The asialoglycoprotein-receptor (ASGP-R) is a C-type lectin predominantly expressed on the sinusoidal surface of mammalian hepatocytes and is responsible for the blood-clearance of desialylated glycoproteins by receptormediated endocytosis.
Stokmaier, Daniela
core   +1 more source

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy

OncoImmunology, 2018
The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor ...
Seandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, Marta Compte, Sara Hernández-Pérez, Nekane Merino, Jaume Bonet, Rocio Navarro, Paul M. P. Van Bergen en Henegouwen, Simon Lykkemark, Kasper Mikkelsen, Kasper Mølgaard, Frederic Jabs, Laura Sanz, Francisco J. Blanco, Pedro Roda-Navarro, Luis Alvarez-Vallina   +16 more
doaj   +1 more source

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

Antibodies, 2019
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yanling Wu, Tianlei Ying   +10 more
doaj   +1 more source

Emerging Antibodies in Cancer Therapy

Advanced NanoBiomed Research, 2023
Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj   +1 more source

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Life, 2021
Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf   +2 more
doaj   +1 more source

The use of non-radioactive iodine as a label in immunoassays [PDF]

, 1995
The research described in this thesis has centered on the development of a nonradioactive iodine label for use in immunoassays. A protein can be iodinated with nonradioactive iodine, used in an immunoassay, and the iodine label detected by a chemical ...
Butler, Mary
core   +2 more sources